Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium
Open Access
- 12 April 2012
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 103 (7), 1334-1341
- https://doi.org/10.1111/j.1349-7006.2012.02306.x
Abstract
Most patients with epithelial ovarian cancer (EOC) are diagnosed at advanced stage and have a poor prognosis. However, a small proportion of these patients will survive, whereas others will die very quickly. Clinicopathological factors do not allow precise identification of these subgroups. Thus, we have validated a molecular subclassification as new prognostic factor in EOC. One hundred and ninety‐four patients with Stage II–IV EOC were characterized by whole‐genome expression profiling of tumor tissues and were classified using a published 112 gene set, derived from an International Federation of Gynecology and Obstetrics (FIGO) stage‐directed supervised classification approach. The 194 tumor samples were classified into two subclasses comprising 95 (Subclass 1) and 99 (Subclass 2) tumors. All nine FIGO II tumors were grouped in Subclass 1 (P = 0.001). Subclass 2 (54% of advanced‐stage tumors) was significantly correlated with peritoneal carcinomatosis and non‐optimal debulking. Patients with Subclass 2 tumors had a worse overall survival for both serous and non‐serous histological subtypes, as revealed by univariate analysis (hazard ratios [HR] of 3.17 and 17.11, respectively; P ≤ 0.001) and in models corrected for relevant clinicopathologic parameters (HR 2.87 and 12.42, respectively; P ≤ 0.023). Significance analysis of microarrays revealed 2082 genes that were differentially expressed in advanced‐grade serous tumors of both subclasses and the focal adhesion pathway as the most deregulated pathway. In the present validation study, we have shown that, in advanced‐stage serous ovarian cancer, two approximately equally large molecular subtypes exist, independent of classical clinocopathological parameters and presenting with highly different whole‐genome expression profiles and a markedly different overall survival. Similar results were obtained in a small cohort of patients with non‐serous tumors. (Cancer Sci 2012; 103: 1334–1341)Keywords
This publication has 26 references indexed in Scilit:
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Calculator for ovarian carcinoma subtype predictionLaboratory Investigation, 2011
- Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathwaysBMC Cancer, 2010
- Breast cancer molecular profiling with single sample predictors: a retrospective analysisThe Lancet Oncology, 2010
- A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysisClinical & Experimental Metastasis, 2009
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical OutcomeClinical Cancer Research, 2008
- Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancerJCI Insight, 2005
- Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2Oncogene, 2004
- Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic DataInternational Journal of Gynecological Pathology, 2004
- Molecular portraits of human breast tumoursNature, 2000